User menu

Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice.

Bibliographic reference Ladjemi, Maha Z ; Chardes, Thierry ; Corgnac, Stephanie ; Garambois, Veronique ; Morisseau, Sebastien ; et. al. Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice.. In: Breast cancer research : BCR, Vol. 13, no.1, p. R17 (2011)
Permanent URL http://hdl.handle.net/2078/122833
  1. Slamon D., Clark G., Wong S., Levin W., Ullrich A, McGuire W., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, 10.1126/science.3798106
  2. Slamon D., Godolphin W, Jones L., Holt J., Wong S., Keith D., Levin W., Stuart S., Udove J, Ullrich A, et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, 10.1126/science.2470152
  3. Nicholson Robert I., McClelland Richard A., Gee Julia M. W., Manning David L., Cannon Peter, Robertson John F. R., Ellis Ian O., Blamey Roger W., Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy, 10.1007/bf00666187
  4. Martin M., Rodriguez-Lescure A., Ruiz A., Alba E., Calvo L., Ruiz-Borrego M., Munarriz B., Rodriguez C. A., Crespo C., de Alava E., Lopez Garcia-Asenjo J. A., Guitian M. D., Almenar S., Gonzalez-Palacios J. F., Vera F., Palacios J., Ramos M., Gracia Marco J. M., Lluch A., Alvarez I., Segui M. A., Mayordomo J. I., Anton A., Baena J. M., Plazaola A., Modolell A., Pelegri A., Mel J. R., Aranda E., Adrover E., Alvarez J. V., Garcia Puche J. L., Sanchez-Rovira P., Gonzalez S., Lopez-Vega J. M., , Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer, 10.1093/jnci/djn151
  5. Disis Mary L, Schiffman Kathy, Salazar Lupe G, Almand Bond, Knutson Keith L, HER-2/neu vaccines, Cancer Chemotherapy and Biological Response Modifiers Annual (2003) ISBN:9780444514585 p.275-285, 10.1016/s0921-4410(03)21013-9
  6. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R, Cheever MA: Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 1994, 54: 16-20.
  7. Peoples G. E., Goedegebuure P. S., Smith R., Linehan D. C., Yoshino I., Eberlein T. J., Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide., 10.1073/pnas.92.2.432
  8. Nanda Navreet K., Sercarz Eli E., Induction of anti-self-immunity to cure cancer, 10.1016/0092-8674(95)90047-0
  9. Disis Mary L., Gooley Theodore A., Rinn Kristine, Davis Donna, Piepkorn Michael, Cheever Martin A., Knutson Keith L., Schiffman Kathy, Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide–Based Vaccines, 10.1200/jco.2002.06.171
  10. Mittendorf Elizabeth A., Storrer Catherine E., Shriver Craig D., Ponniah Sathibalan, Peoples George E., Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides, 10.1007/s10549-005-0988-1
  11. Roth A, Rohrbach F, Weth R, Frisch B, Schuber F, Wels W S, Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct, 10.1038/sj.bjc.6602526
  12. Lollini Pier-Luigi, De Giovanni Carla, Pannellini Tania, Cavallo Federica, Forni Guido, Nanni Patrizia, Cancer immunoprevention, 10.1517/14796694.1.1.57
  13. Gritzapis Angelos D., Mahaira Louisa G., Perez Sonia A., Cacoullos Nike T., Papamichail Michael, Baxevanis Constantin N., Vaccination with Human HER-2/neu(435-443) CTL Peptide Induces Effective Antitumor Immunity against HER-2/neu-Expressing Tumor CellsIn vivo, 10.1158/0008-5472.can-05-4018
  14. Peoples G. E., Holmes J. P., Hueman M. T., Mittendorf E. A., Amin A., Khoo S., Dehqanzada Z. A., Gurney J. M., Woll M. M., Ryan G. B., Storrer C. E., Craig D., Ioannides C. G., Ponniah S., Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02, 10.1158/1078-0432.ccr-07-1448
  15. Jerne NK: Towards a network theory of the immune system. Ann Immunol (Paris). 1974, 125C: 373-389.
  16. Foon KA, John WJ, Chakraborty M, Das R, Teitelbaum A, Garrison J, Kashala O, Chatterjee SK, Bhattacharya-Chatterjee M: Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol. 1999, 17: 2889-2895.
  17. Reinartz S., Vaccination of Patients with Advanced Ovarian Carcinoma with the Anti-Idiotype ACA125: Immunological Response and Survival (Phase Ib/II), 10.1158/1078-0432.ccr-03-0056
  18. Sabbatini P., Dupont J., Aghajanian C., Derosa F., Poynor E., Anderson S., Hensley M., Livingston P., Iasonos A., Spriggs D., McGuire W., Reinartz S., Schneider S., Grande C., Lele S., Rodabaugh K., Kepner J., Ferrone S., Odunsi K., Phase I Study of Abagovomab in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, 10.1158/1078-0432.ccr-05-2670
  19. Foon KA, Lutzky J, Baral RN, Yannelli JR, Hutchins L, Teitelbaum A, Kashala OL, Das R, Garrison J, Reisfeld RA, Bhattacharya-Chatterjee M: Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol. 2000, 18: 376-384.
  20. de Cerio A López-Díaz, Zabalegui N, Rodríguez-Calvillo M, Inogés S, Bendandi M, Anti-idiotype antibodies in cancer treatment, 10.1038/sj.onc.1210371
  21. Coelho M, Gauthier P, Pugnière M, Roquet F, Pèlegrin A, Navarro-Teulon I, Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice, 10.1038/sj.bjc.6601825
  22. Finkle D., HER2-Targeted Therapy Reduces Incidence and Progression of Midlife Mammary Tumors in Female Murine Mammary Tumor Virus huHER2-Transgenic Mice, 10.1158/1078-0432.ccr-03-0448
  23. Curigliano Giuseppe, Spitaleri Gianluca, Dettori Manuela, Locatelli Marzia, Scarano Eloise, Goldhirsch Aron, Vaccine immunotherapy in breast cancer treatment: promising, but still early, 10.1586/14737140.7.9.1225
  24. Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, Dennis PA, Lipkowitz S: Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 2001, 61: 4892-4900.
  25. Felici Franco, Luzzago Alessandra, Folgori Antonella, Cortese Riccardo, Mimicking of discontinuous epitopes by phage-displayed peptides, II. Selection of clones recognized by a protective monoclonal antibody against the Bordetella pertussis toxin from phage peptide libraries, 10.1016/0378-1119(93)90148-v
  26. Cho Hyun-Soo, Mason Karen, Ramyar Kasra X., Stanley Ann Marie, Gabelli Sandra B., Denney Dan W., Leahy Daniel J., Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab, 10.1038/nature01392
  27. Geysen H.Mario, Rodda Stuart J., Mason Tom J., A priori delineation of a peptide which mimics a discontinuous antigenic determinant, 10.1016/0161-5890(86)90081-7
  28. Riemer A. B., Klinger M., Wagner S., Bernhaus A., Mazzucchelli L., Pehamberger H., Scheiner O., Zielinski C. C., Jensen-Jarolim E., Generation of Peptide Mimics of the Epitope Recognized by Trastuzumab on the Oncogenic Protein Her-2/neu, 10.4049/jimmunol.173.1.394
  29. Riemer Angelika B., Kraml Georg, Scheiner Otto, Zielinski Christoph C., Jensen-Jarolim Erika, Matching of trastuzumab (Herceptin®) epitope mimics onto the surface of Her-2/neu – a new method of epitope definition, 10.1016/j.molimm.2004.11.003
  30. Kosmaczewska Agata, Ciszak Lidia, Potoczek Stanisław, Frydecka Irena, The significance of Treg cells in defective tumor immunity, 10.1007/s00005-008-0018-1
  31. Crone Steven A., Zhao You-Yang, Fan Lian, Gu Yusu, Minamisawa Susumu, Liu Yang, Peterson Kirk L., Chen Ju, Kahn Ronald, Condorelli Gianluigi, Jr John Ross, Chien Kenneth R., Lee Kuo-Fen, ErbB2 is essential in the prevention of dilated cardiomyopathy, 10.1038/nm0502-459
  32. Slamon Dennis J., Leyland-Jones Brian, Shak Steven, Fuchs Hank, Paton Virginia, Bajamonde Alex, Fleming Thomas, Eiermann Wolfgang, Wolter Janet, Pegram Mark, Baselga Jose, Norton Larry, Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2, 10.1056/nejm200103153441101
  33. Curigliano G., Breast cancer vaccines: a clinical reality or fairy tale?, 10.1093/annonc/mdj083